Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

Emens, LA; Esteva, FJ; Beresford, M; Saura, C; De Laurentiis, M; Kim, SB; Im, SA; Wang, YF; Salgado, R; Mani, A; Shah, J; Lambertini, C; Liu, HY; de Haas, SL; Patre, M; Loi, S

Emens, LA (corresponding author), Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA 15213 USA.

LANCET ONCOLOGY, 2020; 21 (10): 1283

Abstract

Background HER2-positive metastatic breast cancer is incurable and new treatments are needed. Addition of atezolizumab to trastuzumab emtansine might ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索